Clinical Trials Logo

Hyperplasia clinical trials

View clinical trials related to Hyperplasia.

Filter by:

NCT ID: NCT00303368 Completed - Clinical trials for Neurofibromatosis Type 1

Neurofibromatosis Type 1 (NF1) and Tibial Dysplasia

NF1TD
Start date: March 2004
Phase:
Study type: Observational

The study is a multicenter four-year outcome study of the natural history of tibial dysplasia in patients with NF1 and selected patients without NF1. We will obtain information on the natural history, burden, functional and health status, health-related quality of life, and surgical interventions/outcomes of tibial dysplasia. The project will also establish a Core Facility (NOCF) for tissue samples for future studies.

NCT ID: NCT00290030 Completed - Clinical trials for Prostatic Hyperplasia

ALFAURUS : A DB Randomized Parallel Group Study of Alfuzosin 10mg OD vs Placebo in the Management of AUR in Patients With a 1st Episode Due to BPH

Start date: May 2001
Phase: Phase 3
Study type: Interventional

To assess the efficacy of alfuzosin 10mg OD in the management of acute urinary retention associated with BPH. To assess the safety of alfuzosin in this population and health care consumption.

NCT ID: NCT00284518 Completed - Clinical trials for Benign Prostatic Hyperplasia

Safety and Efficacy Study of Botulinum Toxin Type A to Treat Lower Urinary Symptoms Due to Benign Prostatic Hyperplasia

Start date: December 2005
Phase: Phase 2
Study type: Interventional

The purpose of this study was to determine the safety and effectiveness of different doses of botulinum toxin Type A in treating lower urinary tract symptoms due to benign prostatic hyperplasia.

NCT ID: NCT00280605 Completed - Clinical trials for Prostatic Hyperplasia

ALF-ONE : ALFuzosin ONcE Daily

Start date: August 2005
Phase: Phase 4
Study type: Interventional

The aim of the study is to collect, under daily practice conditions, clinical data on the safety profile and the efficacy of a new formulation of alfuzosin administered once daily in patients with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH).

NCT ID: NCT00242710 Completed - Osteoporosis Clinical Trials

Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women

Start date: September 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether bazedoxifene/conjugated estrogens combinations are effective for the prevention of endometrial hyperplasia and for the prevention of osteoporosis in postmenopausal women.

NCT ID: NCT00224133 Completed - Clinical trials for Benign Prostatic Hyperplasia

The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 Months

Start date: September 2005
Phase: Phase 3
Study type: Interventional

A new drug for benign prostatic hyperplasia is used for 9 months to determine its long-term safety.

NCT ID: NCT00224120 Completed - Clinical trials for Benign Prostatic Hyperplasia

A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo

Start date: May 2005
Phase: Phase 3
Study type: Interventional

A new drug for benign prostatic hyperplasia is compared to placebo for to determine if it is safe and effective. The study lasts approximately 20 weeks.

NCT ID: NCT00224107 Completed - Clinical trials for Benign Prostatic Hyperplasia (BPH)

A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo

Start date: May 2005
Phase: Phase 3
Study type: Interventional

A new drug for benign prostatic hyperplasia is compared to placebo for to determine if it is safe and effective. The study lasts approximately 20 weeks.

NCT ID: NCT00199550 Completed - Clinical trials for Benign Prostatic Hyperplasia

Bipolar vs Monopolar Transurethral Resection of the Prostate (TURP)

Start date: May 2004
Phase: Phase 4
Study type: Interventional

This study will prospectively evaluate a new electrosurgical procedure (bipolar transurethral prostatectomy) in men with symptomatic benign prostatic hyperplasia.

NCT ID: NCT00194675 Completed - Clinical trials for Benign Prostatic Hyperplasia

TRADE-Testosterone Replacement and Dutasteride Effectiveness

TRADE
Start date: March 2005
Phase: Phase 4
Study type: Interventional

The purpose of this research study is to determine whether the combination of the male hormone testosterone [T] in gel form and the oral drug dutasteride [D], used to shrink large prostate glands can safely reduce the size of the prostate gland and symptoms of prostate enlargement (called benign prostatic hyperplasia [BPH]) compared to T treatment alone in men with low testosterone (called hypogonadism).